New hope for controlling breast cancer in the brain
NCT ID NCT07251868
Summary
This study is observing how well an existing drug called Trop-2 ADC (sacituzumab govitecan) works for breast cancer patients whose cancer has spread to the brain. Researchers will collect data from about 100 patients already receiving this drug in their normal care at multiple hospitals. The main goal is to see if the drug helps control the brain tumors and to understand its side effects in real-world practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.